Deirdre Mladsi

Deirdre Mladsi

Auto-generated profile, based on publicly available information

Deirdre Mladsi

RTI Health Solutions, Research Triangle Park, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2009 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
MJMelissa Juniper
Melissa Juniper
TLTrong Kim Le
Trong Kim Le
DMDeirdre Mladsi
Deirdre Mladsi
MSMs
Ms
MPMph
Mph
Objective: This study's objective was to review the literature on the epidemiological and economic burden and treatment of chronic low back pain (CLBP) in France, Germany, Italy, Spain and the UK. Methods: A literature search was conducted for 1997 – 2007, focusing on CLBP burden and treatment in the countries of interest. Results: The literature search yielded 1552 articles; 23 sources were included in this review. General population prevalence estimates for CLBP were available for two countries: 5.91% (Italy) and 6.3 – 11.1% (UK). Resource utilization estimates were available for Germany, Italy, Spain and the UK. Patients visited general practitioners and osteopaths. Annual direct costs of low back pain were available only for Germany: > € 7000 per person. Work absenteeism accounted for 75% of the total per-patient cost of low back pain in Germany. The five identified treatment guidelines recommended a multimodal approach. Recommended pharmacotherapies included NSAIDs, muscle relaxants, analgesics and a...

1 September 2013 in Value in Health
Verified
Journal Article
Closed access
WRW. Ken Redekop
W. Ken Redekop
DMDeirdre Mladsi
Deirdre Mladsi

1 July 2020 in Clinical and Experimental Gastroenterology
Verified
Journal Article
Open access
PDF file
ANArpita Nag
Arpita Nag
SMSusan A Martin
Susan A Martin
DMDeirdre Mladsi
Deirdre Mladsi
OOOyebimpe Olayinka-Amao
Oyebimpe Olayinka-Amao
MPMolly Purser
Molly Purser
RVRenu M Vekaria
Renu M Vekaria
Background: Chronic idiopathic constipation (CIC) is a functional gastrointestinal disorder with an estimated prevalence of 16% in the USA; however, the humanistic and economic burden of CIC is poorly characterized. Aim: This systematic literature review aimed to assess the humanistic and economic burden of CIC in adults in the USA. Methods: Two systematic literature searches of English-language publications on the humanistic and economic burden of CIC in adults in the USA were conducted using electronic databases and other resources. Both searches included the terms “chronic idiopathic constipation” and “functional constipation”. Specific terms used in the search on humanistic burden included “quality of life”, “SF-36”, “SF-12”, and “PAC-QOL”; search terms for economic burden included “cost”, “resource use”, “absenteeism”, and “productivity”. Results: Overall, 16 relevant articles were identified. Health-related quality of life (HRQoL) appeared to be reduced in patients with CIC compared with controls and the general US population. Abdominal (r=0.33– 0.49), stool (r=0.23– 0.33), and rectal symptoms (r=0.53) appeared to be associated with reduced HRQoL. Younger age and female sex were associated with reduced overall HRQoL and greater symptom severity. Direct outpatient costs were higher in patients with CIC than those without CIC (US$6284 vs US$5254). Patients with CIC and abdominal symptoms reported more days of disrupted productivity per month than those without abdominal symptoms (3.2 days vs 1.2 days). The overall prevalence of complementary and alternative medicine use by patients with CIC was similar to that in the general US population. Conclusion: The reduced HRQoL and increased costs associated with CIC indicate unmet therapeutic need in this disorder. Further research is required to better understand the humanistic and economic burden of CIC in the USA.

23 May 2014 in Clinical Therapeutics
Verified
Journal Article
Open access
PDF file
DODawn M. Odom
Dawn M. Odom
DMDeirdre M. Mladsi
Deirdre M. Mladsi
KSKenneth G. Saag
Kenneth G. Saag
BSBintu N. Sherif
Bintu N. Sherif
LMLaStella Miles
LaStella Miles
JWJianmin Wang
Jianmin Wang
NSAIDs are a diverse group of medications used to treat patients with acute and chronic pain as well as to reduce inflammation.1 x 1 McCarberg, B. and Gibofsky, A. Need to develop new nonsteroidal anti-inflammatory drug formulations. Clin Ther. 2012; 34: 1954–1963 Abstract | Full Text | Full Text PDF | PubMed | Scopus (20) | Google Scholar See all References Although NSAIDs are commonly prescribed due to their proven efficacy in treating pain, they often present safety and tolerability issues, including serious concerns related to gastrointestinal (GI), cardiovascular (CV), and renal toxicity. Traditional, nonselective NSAIDs such as diclofenac have been associated with GI events and in particular upper GI bleeding/perforation (UGIB).2 x 2 Wolfe, M.M., Lichtenstein, D.R., and Singh, G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340: 1888–1899 Crossref | PubMed | Scopus (1732) | Google Scholar See all References Efforts have been taken to mediate NSAID toxicity, including use of proton pump inhibitors for their gastroprotective effects, development of cyclooxygenase-2 (COX-2) selective inhibitors, and development of topical NSAIDs. Newer, COX-2–selective NSAIDs were developed in part for the potential to reduce the risk of GI events but have subsequently demonstrated an increased risk of CV events. In particular, rofecoxib, a COX-2–selective inhibitor, was removed from the market in late 2004 when a clinical study demonstrated that the drug was associated with increased rates of CV events in patients with colorectal polyps.3 x 3 Bresalier, R.S., Sandler, R.S., Quan, H...., and for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092–1102 Crossref | PubMed | Scopus (2031) | Google Scholar See all References Subsequently, efforts focused on understanding whether the risks observed with rofecoxib were also present for other COX-2–selective inhibitors and for nonselective NSAIDs.

2 July 2018 in Journal of Medical Economics
Verified
Journal Article
Closed access
CBChristine L. Barnett
Christine L. Barnett
DMDeirdre Mladsi
Deirdre Mladsi
MVMichael Vredenburg
Michael Vredenburg
KAKavita Aggarwal
Kavita Aggarwal
Aims: This study aimed to estimate the cost of platelet transfusion in patients with chronic liver disease (CLD)-associated thrombocytopenia undergoing an elective procedure in the United States. Materials and methods: The study was conducted in two parts: development of a conceptual framework identifying direct, indirect and intangible costs of platelet transfusion, followed by the estimation of the total cost of platelet transfusion in patients with CLD-associated thrombocytopenia before an elective procedure in the United States using the conceptual framework and cost data obtained from a literature search. The cost of the entire care required to raise a patient’s platelet count before the procedure was considered. Results: The final conceptual framework included the costs of generating the supply of platelets, the platelet transfusion itself, adverse events associated with platelet transfusion and refractoriness to platelet transfusion. When costs were accounted for in all the framework cost categories, the total direct cost of a platelet transfusion in a patient with CLD and associated thrombocytopenia was estimated to be in the range of $5258 to $13,117 (2017 US dollars) in the United States. The largest portion of costs was incurred by the transfusion event itself ($3723 to $4436) and the cost of refractoriness ($874 to $7578), which included the opportunity cost of a delayed procedure and subsequent platelet transfusions with human leukocyte antigen-matched platelets. Limitations and conclusions: Although we were unable to include all cost components identified in the conceptual framework in our total cost estimate, thus likely underestimating the true total cost, and despite the data gaps and challenges limiting our estimate of the full cost of a platelet transfusion in patients with CLD-associated thrombocytopenia undergoing an elective procedure in the United States, this study outlines a comprehensive conceptual framework for estimating the cost elements of a platelet transfusion in these patients.

1 January 2017 in Journal of Skin Cancer
Verified
Journal Article
Open access
PDF file
DODawn Odom
Dawn Odom
DMDeirdre Mladsi
Deirdre Mladsi
MPMolly Purser
Molly Purser
JKJames A. Kaye
James A. Kaye
EPEirini Palaka
Eirini Palaka
DSDalila Sellami
Dalila Sellami
Objectives. Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy. Vismodegib, the other approved targeted therapy, also was assessed in a single-arm trial (ERIVANCE). We examined the comparative effectiveness of the two drugs using a matching-adjusted indirect comparison (MAIC) versus an unadjusted indirect comparison. Methods. After comparing trials and identifying potential prognostic factors, an MAIC was conducted to adjust for differences in key patient baseline characteristics. Due to BOLT’s small sample size, the number of matching variables was restricted to two. Efficacy results for sonidegib were generated so that selected baseline characteristics matched those from ERIVANCE and were compared with published ERIVANCE results. Results. Matching variables were baseline percentages of patients receiving prior radiotherapy and surgery. After weighting, sonidegib objective response rate (ORR) and median progression-free survival (PFS) were effectively unchanged (prematched versus postmatched ORR and PFS, 56.1% versus 56.7% and 22.1 versus 22.1 months, resp.). Vismodegib’s ORR and PFS were 47.6% and 9.5 months. Conclusions. Comparative effectiveness of sonidegib versus vismodegib remains unchanged after adjusting BOLT patient-level data to match published ERIVANCE baseline percentages of patients receiving prior surgery and radiotherapy.